fruquintinib
takeda
['crcsm', 'fruquintinib', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)']
fruquintinib/bsc demonstrates os/pfs benefit in refractory mcrc, irrespective of prior treatment #asco23 #crcsm #oncology 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.